Involvement of Heparan Sulfate and Heparanase in Neural Development and Pathogenesis of Brain Tumors
- 10 April 2020
- book chapter
- Published by Springer Nature
- Vol. 1221, 365-403
Abstract
Brain tumors are aggressive and devastating diseases. The most common type of brain tumor, glioblastoma (GBM), is incurable and has one of the worst five-year survival rates of all human cancers. GBMs are invasive and infiltrate healthy brain tissue, which is one main reason they remain fatal despite resection, since cells that have already migrated away lead to rapid regrowth of the tumor. Curative therapy for medulloblastoma (MB), the most common pediatric brain tumor, has improved, but the outcome is still poor for many patients, and treatment causes long-term complications. Recent advances in the classification of pediatric brain tumors reveal distinct subgroups, allowing more targeted therapy for the most aggressive forms, and sparing children with less malignant tumors the side-effects of massive treatment. Heparan sulfate proteoglycans (HSPGs), main components of the neurogenic niche, interact specifically with a large number of physiologically important molecules and vital roles for HS biosynthesis and degradation in neural stem cell differentiation have been presented. HSPGs are composed of a core protein with attached highly charged, sulfated disaccharide chains. The major enzyme that degrades HS is heparanase (HPSE), an important regulator of extracellular matrix (ECM) remodeling which has been suggested to promote the growth and invasion of other types of tumors. This is of clinical interest because GBM are highly invasive and children with metastatic MB at the time of diagnosis exhibit a worse outcome. Here we review the involvement of HS and HPSE in development of the nervous system and some of its most malignant brain tumors, glioblastoma and medulloblastoma.Keywords
This publication has 199 references indexed in Scilit:
- Mechanisms of heparanase inhibition by the heparan sulfate mimetic PG545 and three structural analoguesFEBS Open Bio, 2013
- Expression of the progenitor marker NG2/CSPG4 predicts poor survival and resistance to ionising radiation in glioblastomaActa Neuropathologica, 2011
- Significance of Heparanase in Cancer and InflammationCancer Microenvironment, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- PG545, a dual heparanase and angiogenesis inhibitor, induces potent anti-tumour and anti-metastatic efficacy in preclinical modelsBritish Journal of Cancer, 2011
- TGF-β Receptor Inhibitors Target the CD44high/Id1high Glioma-Initiating Cell Population in Human GlioblastomaCancer Cell, 2010
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell, 2010
- Medulloblastoma Can Be Initiated by Deletion of Patched in Lineage-Restricted Progenitors or Stem CellsCancer Cell, 2008
- A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignanciesCancer Chemotherapy and Pharmacology, 2008
- Effect of dalteparin and radiation on survival and thromboembolic events in glioblastoma multiforme: a phase II ECOG trialCancer Chemotherapy and Pharmacology, 2007